A Phase 2 interventional study of warfarin 1mg and dabigatran etexilate intermediate dose in Heart Valve Diseases, sponsored by Boehringer Ingelheim. Terminated at 40 sites in 10 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2014-08-06.
Sponsored by Boehringer Ingelheim · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 39 studies in Heart Valve Diseases with a site in Canada — 9 open to participants now, 14 under way, none of them phase 3. Heart Valve Diseases · Canada.
Among the 39 studies in Heart Valve Diseases with a site in Canada, this one is the 13th largest by enrollment of the 32 interventional ones that give a count, is one of 4 that started in 2011, is one of 3 in phase 2, and was the 15th registered.
556 studies on the registry are indexed under Heart Valve Diseases; 166 are open to participants now.
Browse Heart Valve Diseases studies →9 of the 39 studies in Heart Valve Diseases with a site in Canada are open now. Recruiting first, the newest first:
TRiCares · Sites in Canada, United States
Ages 18+
Montreal Heart Institute · Sites in Canada, United States, France and 2 more countries
Ages 18+
Montefiore Medical Center · Sites in Canada, United States, Denmark and 5 more countries
Ages 18+
Corcym S.r.l · Sites in Canada, United States, Austria and 10 more countries
Erasmus Medical Center · Sites in Canada, United States, Austria and 9 more countries
Ages 18+
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 119 Heart Valve Diseases studies recruiting now, 94 (79%) set no upper age limit and 10 (8%) stop at 75 or younger; 16 take children under 18; 15 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
39 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 4 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 328 is above the median of 100 across 314 interventional studies indexed under Heart Valve Diseases.
Median enrollment 245 across the 32 interventional studies, 400 across the 7 observational. Of the 20 that completed or were terminated, 9 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 39 have an industry lead sponsor. The 10 most frequent:
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
Boehringer Ingelheim has 1 study filed under Heart Valve Diseases — fewer than ten, so there is no comparison to draw.
7 of the studies in Heart Valve Diseases with a site in Canada that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06816888Ottawa Heart Institute Research CorporationImpact of Automatic Prompts in Echocardiographic Reports on Referral to Cardiology | 2026-12-01 |
| NCT03142152Cardiac Dimensions, Inc.The EMPOWER Trial - The Carillon Mitral Contour System® in Treating Heart Failure With FMR | 2026-12-31 |
| NCT04913870Institut universitaire de cardiologie et de pneumologie de Québec, University LavalAngiotensin Receptor Blockers in Aortic Stenosis | 2027-02 |
| NCT06506942TRiCaresThe TRICURE EFS Study | 2027-03 |
| NCT05932615Abbott Medical DevicesENVISION IDE Trial: Safety and Effectiveness of NAVITOR in Transcatheter Aortic Valve Implantation | 2027-04 |
Add all 7 to your calendar (.ics) → With an account.
Among the 39 studies in Heart Valve Diseases with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To validate the dosing algorithm for dabigatran etexilate in patients receiving a mechanical heart valve.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Patient dose dependent on screening CrCl levels and TT
Drug: dabigatran etexilate intermediate dose · Drug: dabigatran etexilate low dose · Drug: dabigatran etexilate high dose
warfarin doses to maintain INR levels
Drug: warfarin 1mg · Drug: warfarin 5mg · Drug: warfarin 3mg
comparator warfarin
active treatment (medium)
active treatment (low)
comparator warfarin
active treatment (high)
comparator warfarin
Comparison of Observed and Predicted Trough Dabigatran Plasma Concentrations at Steady State (C Trough,ss) at Week 1
Comparisons between dabigatran trough plasma levels as predicted by simulations to those observed in the study are performed to validate the dosing algorithm for Dabigatran Etexilate (DE) . Despite the primary endpoint only being assessed in patients who received dabigatran etexilate, Warfarin was included as a comparator treatment in this study in order to facilitate informal comparisons of outcome events, and to look for efficacy signals in this previously unexplored population.
Time frame: Week 1
Comparison of Observed and Predicted Trough Dabigatran Plasma Concentrations (C Trough,ss) at Week 2
Comparisons between dabigatran trough plasma levels as predicted by simulations to those observed in the study are performed to validate the dosing algorithm for Dabigatran Etexilate (DE). Despite the primary endpoint only being assessed in patients who received dabigatran etexilate, Warfarin was included as a comparator treatment in this study in order to facilitate informal comparisons of outcome events, and to look for efficacy signals in this previously unexplored population.
Time frame: Week 2
Comparison of Observed and Predicted Trough Dabigatran Plasma Concentrations (C Trough,ss) at Week 4
Comparisons between dabigatran trough plasma levels as predicted by simulations to those observed in the study are performed to validate the dosing algorithm for Dabigatran Etexilate (DE). Despite the primary endpoint only being assessed in patients who received dabigatran etexilate, Warfarin was included as a comparator treatment in this study in order to facilitate informal comparisons of outcome events, and to look for efficacy signals in this previously unexplored population.
Time frame: Week 4
Comparison of Observed and Predicted Trough Dabigatran Plasma Concentrations (C Trough,ss) at End of Trial (EoT) at Week 12
Comparisons between dabigatran trough plasma levels as predicted by simulations to those observed in the study are performed to validate the dosing algorithm for Dabigatran Etexilate (DE). (As the trial was stopped prematurely, EOT may not be 12 weeks after randomisation for most of the patients) Despite the primary endpoint only being assessed in patients who received dabigatran etexilate, Warfarin was included as a comparator treatment in this study in order to facilitate informal comparisons of outcome events, and to look for efficacy signals in this previously unexplored population.
Time frame: Week 12
Percentage of Patients With Observed Trough Dabigatran Plasma Concentrations < 50 ng/mL at Week 1
Percentage of patients with observed Ctrough,ss value \< 50 ng/mL are presented. This outcome measure was only analysed for all patients together and not by dose group.
Time frame: Week 1
Percentage of Patients With Observed Trough Dabigatran Plasma Concentrations < 50 ng/mL at Week 2
Percentage of patients with observed Ctrough,ss value \< 50 ng/mL are presented. This outcome measure was only analysed for all patients together and not by dose group.
Time frame: Week 2
Percentage of Patients With Observed Trough Dabigatran Plasma Concentrations < 50 ng/mL at Week 4
Percentage of patients with observed Ctrough,ss value \< 50 ng/mL are presented. This outcome measure was only analysed for all patients together and not by dose group.
Time frame: Week 4
Percentage of Patients With Observed Trough Dabigatran Plasma Concentrations < 50 ng/mL at End of Trial (EoT) Week 12
Percentage of patients with observed Ctrough,ss value \< 50 ng/mL (As the trial was stopped prematurely, EOT may not be 12 weeks after randomisation for most of the patients) This outcome measure was only analysed for all patients together and not by dose group.
Time frame: Week 12
| Milestone | Dabigatran Etexilate (DE) | Warfarin |
|---|---|---|
| Started | 168 | 84 |
| Completed | 151 | 77 |
| Not completed | 17 | 7 |
| Withdrew: Adverse event | 2 | 1 |
| Withdrew: Non compliance protocol | 2 | 0 |
| Withdrew: Lost to follow-up | 2 | 0 |
| Withdrew: Withdrawal by subject | 3 | 3 |
| Withdrew: Not treated | 6 | 3 |
| Withdrew: Other reason not defined above | 2 | 0 |
Comparisons between dabigatran trough plasma levels as predicted by simulations to those observed in the study are performed to validate the dosing algorithm for Dabigatran Etexilate (DE) . Despite the primary endpoint only being assessed in patients who received dabigatran etexilate, Warfarin was included as a comparator treatment in this study in order to facilitate informal comparisons of outcome events, and to look for efficacy signals in this previously unexplored population.
| ng/mL | Observed | Predicted |
|---|---|---|
| Comparison of Observed and Predicted Trough Dabigatran Plasma Concentrations at Steady State (C Trough,ss) at Week 1 | 73.86 ± 43.9 | 99.52 ± 43.9 |
Comparisons between dabigatran trough plasma levels as predicted by simulations to those observed in the study are performed to validate the dosing algorithm for Dabigatran Etexilate (DE). Despite the primary endpoint only being assessed in patients who received dabigatran etexilate, Warfarin was included as a comparator treatment in this study in order to facilitate informal comparisons of outcome events, and to look for efficacy signals in this previously unexplored population.
| ng/mL | Observed | Predicted |
|---|---|---|
| Comparison of Observed and Predicted Trough Dabigatran Plasma Concentrations (C Trough,ss) at Week 2 | 84.08 ± 40.2 | 99.55 ± 40.2 |
Comparisons between dabigatran trough plasma levels as predicted by simulations to those observed in the study are performed to validate the dosing algorithm for Dabigatran Etexilate (DE). Despite the primary endpoint only being assessed in patients who received dabigatran etexilate, Warfarin was included as a comparator treatment in this study in order to facilitate informal comparisons of outcome events, and to look for efficacy signals in this previously unexplored population.
| ng/mL | Observed | Predicted |
|---|---|---|
| Comparison of Observed and Predicted Trough Dabigatran Plasma Concentrations (C Trough,ss) at Week 4 | 104.43 ± 34.3 | 109.36 ± 34.3 |
Comparisons between dabigatran trough plasma levels as predicted by simulations to those observed in the study are performed to validate the dosing algorithm for Dabigatran Etexilate (DE). (As the trial was stopped prematurely, EOT may not be 12 weeks after randomisation for most of the patients) Despite the primary endpoint only being assessed in patients who received dabigatran etexilate, Warfarin was included as a comparator treatment in this study in order to facilitate informal comparisons of outcome events, and to look for efficacy signals in this previously unexplored population.
| ng/mL | Observed | Predicted |
|---|---|---|
| Comparison of Observed and Predicted Trough Dabigatran Plasma Concentrations (C Trough,ss) at End of Trial (EoT) at Week 12 | 108.21 ± 59.8 | 104.80 ± 59.8 |
Percentage of patients with observed Ctrough,ss value \< 50 ng/mL are presented. This outcome measure was only analysed for all patients together and not by dose group.
| percentage of participants | Patients Evaluated |
|---|---|
| Percentage of Patients With Observed Trough Dabigatran Plasma Concentrations < 50 ng/mL at Week 1 | 26.9 |
Percentage of patients with observed Ctrough,ss value \< 50 ng/mL are presented. This outcome measure was only analysed for all patients together and not by dose group.
| percentage of participants | Patients Evaluated |
|---|---|
| Percentage of Patients With Observed Trough Dabigatran Plasma Concentrations < 50 ng/mL at Week 2 | 19.2 |
Percentage of patients with observed Ctrough,ss value \< 50 ng/mL are presented. This outcome measure was only analysed for all patients together and not by dose group.
| percentage of participants | Patients Evaluated |
|---|---|
| Percentage of Patients With Observed Trough Dabigatran Plasma Concentrations < 50 ng/mL at Week 4 | 9.8 |
Percentage of patients with observed Ctrough,ss value \< 50 ng/mL (As the trial was stopped prematurely, EOT may not be 12 weeks after randomisation for most of the patients) This outcome measure was only analysed for all patients together and not by dose group.
| percentage of participants | Patients Evaluated |
|---|---|
| Percentage of Patients With Observed Trough Dabigatran Plasma Concentrations < 50 ng/mL at End of Trial (EoT) Week 12 | 7.4 |
Collected over From first intake of study drug until last intake of study drug plus 6 days (Up to 101 days).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dabigatran Etexilate | — | 19/162 (11.7%) | 64/162 (39.5%) |
| Warfarin | — | 11/89 (12.4%) | 38/89 (42.7%) |
| Event | Dabigatran Etexilate | Warfarin |
|---|---|---|
| Atrial fibrillationCardiac disorders | 5/162 | 1/89 |
| Pericardial effusionCardiac disorders | 5/162 | 0/89 |
| Wound infection staphylococcalInfections and infestations | 0/162 | 1/89 |
| Loss of consciousnessNervous system disorders | 0/162 | 1/89 |
| Prinzmetal anginaCardiac disorders | 0/162 | 1/89 |
| HypertensionVascular disorders | 1/162 | 1/89 |
| Back painMusculoskeletal and connective tissue disorders | 0/162 | 1/89 |
| Chest painGeneral disorders | 0/162 | 1/89 |
| Impaired healingGeneral disorders | 0/162 | 1/89 |
| Ejection fraction decreasedInvestigations | 0/162 | 1/89 |
| Event | Dabigatran Etexilate | Warfarin |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 19/162 | 2/89 |
| Atrial fibrillationCardiac disorders | 11/162 | 9/89 |
| DyspepsiaGastrointestinal disorders | 15/162 | 0/89 |
| Pericardial effusionCardiac disorders | 8/162 | 7/89 |
| ConstipationGastrointestinal disorders | 10/162 | 7/89 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 11/162 | 3/89 |
| CoughRespiratory, thoracic and mediastinal disorders | 8/162 | 6/89 |
| Oedema peripheralGeneral disorders | 10/162 | 2/89 |
| Urinary tract infectionInfections and infestations | 5/162 | 5/89 |
| DizzinessNervous system disorders | 3/162 | 5/89 |
Treated Set (TRT): The set of patients who received at least 1 dose of study medication
| Age, Continuous(years) | Dabigatran Etexilate (DE) | Warfarin | Total |
|---|---|---|---|
| Mean | 56.3 ± 9.2 | 55.8 ± 10.2 | 56.2 ± 9.5 |
| Sex: Female, Male(Participants) | Dabigatran Etexilate (DE) | Warfarin | Total |
|---|---|---|---|
| Female | 60 | 26 | 86 |
| Male | 102 | 55 | 157 |
The record gives a start of Oct 2011, a primary completion of Jun 2013 and a completion of Jun 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2014, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.